tbuckley/cabot-search huggingface dataset:
제 7 차 춘계학술대회 초록집 : 포스터 발표 ; 만성 B 형 간염에서 lamivudine 치료 중 발생한 viral breakthrough 예의 임상경과
Authors: 김지훈, 공휘, 조남영, 백수정, 손수민, 김윤홍, 정길만, 연종은, 김재선, 박영태, 변관수, 이창홍
Journal: Clinical and Molecular Hepatology (2001)
High-risk gestational trophoblastic disease: Fifteen years of experience
Authors: G. L. Moura, R. Pasquini, S. Padilha, K. Viana, S. Minucelli, A. G. Silva, L. Albini
Journal: Journal of Clinical Oncology (2005)

5126 Background: The objective of this study was to evaluate the tocixity, efficaccy, overal survival and pregnacy after EMA/CO in high-risk getational trophoblastic tumors. Methods: From 1988 to 2003, forty one patients with high-risk gestational trophoblastic neoplasia were treated with 284 EMA/CO treatment cycles. Most cases were FIGO stage III. Twenty one patients received prior chemotherapy Results: The mean age was 28,6 years and the mean number of cycles was seven. There were no tocicity related death. Two patientes received whole brain radiation therapy and surgery was used in two cases. Of the 41 treated patients, 37 (90, 2%) achieved complete response. Four patients developed resintence and were treated with platinum based chemotherapy achieving remission. One patient died of progressive disease. The tocicity was grade 3 and 4 in 37,8% of the patients. Prophylatic intrathecal methotrexate was not given. Haemopoietic growth factor was used in seven patients.The overal survival was 97,6% (40/41) in this serie. A questionnaire was used to evaluate pregnancy. Response rate was 68,2% (28/41). After EMA/CO 14 patients concieved and 25 pregnancies occured. No fetal abnormalities were reported. Conclusions: EMA/CO is well tolerated and highly effective regimen for hifh risk GTT. Complications from EMA/CO were mainly myelosuppession beig dose-limiting. The response rate was 90,2% and overal survival was 97,6% in this serie. The need for prophylactic intrathecal methotrexate should be reviewed since there where no CNS recurrence during the follow-up. Pregnancy and late side effects as well as quality of life and long term psychosocial sequelae should be better evalute in future studies. No significant financial relationships to disclose.
Detection of circulating lymphendothelial cells in patients with solid tumors
Authors: W. Fiedler, K. Suhrbier, S. Riethdorf, G. Schuch, K. Pantel, C. Bokemeyer, S. Loges
Journal: Journal of Clinical Oncology (2006)

20010 Background: Bone marrow derived endothelial progenitor cells (ECPs) contribute to neoangiogenesis in cancer patients. Elevated numbers of circulating endothelial cells and EPCs can be detected in the peripheral blood of tumor patients. Recently, proliferating lymphatic vessels have been described in human cancers such as melanoma and head and neck tumors. Therefore, we investigated whether circulating lymphatic endothelial cells can be detected in cancer patients. Methods: We developed a sensitive immunocytochemical approach using a monoclonal antibody against the lymphendothelial specific hyaluronic receptor LYVE. After enrichment by Ficoll density gradient centrifugation, 7 × 10(5) peripheral blood mononuclear cells (PBMNCs) from 23 patients with metastatic cancer (6 gastrointestinal, 4 lung, 3 thymus, 3 thyroid, 1 mamma, 1 pancreas, 2 renal, 1 adrenal, 2 urothelial cancer, 1 PNET, 1 NET) and healthy individuals (n = 7) were spun onto glass slides. Two million PBMNs from each patient were stained for LYVE using the APAP technique. Isotype antibodies were used as controls. Cytospins were analyzed with the automated cellular imaging system (ACIS; ChromaVision Medical Systems). The method was validated with spiked blood samples. Results: Circulating LYVE+ lymphatic endothelial cells could be detected in 4 of 7 healthy subjects (57%) and in 16 of 23 patients (69%) with metastatic cancer. The mean number of lymphendothelial cells was significantly higher in cancer patients (15 cells/1 × 10(6) PBMNCs [range 0–276] vs. 1.0 cells/1 × 10(6) PBMNCs [range 0–2]). As a control, circulating tumor cells were enumerated after staining with a cytokeratin antibody (A45-B/B3). Circulating tumor cells could not be detected in healthy controls but in 13 of 23 of cancer patients (mean 1.4 cells/1 × 10(6) PBMNCs range [0–9]). Conclusion: Circulating lymphendothelial cells can be detected in patients with metastatic cancer and healthy subjects. Tumor patients have higher levels of circulating lymphendothelial cells than normal controls. These cells may participate in the generation of lymphatic vessels within tumor manifestations. No significant financial relationships to disclose.
Latent Infection and Malignant Lymphoma in Marmosets (Callithrix jacchus) After Infection With Two Oncogenic Herpesviruses From Primates23
Authors: Rainer Laufs, Hans Steinke, Steinke Gisela, Dieter Petzold
Journal: JNCI Journal of the National Cancer Institute (1974)

Journal Article Latent Infection and Malignant Lymphoma in Marmosets (Callithrix jacchus) After Infection With Two Oncogenic Herpesviruses From Primates Get access Rainer Laufs, Rainer Laufs Search for other works by this author on: Oxford Academic PubMed Google Scholar Hans Steinke, Hans Steinke Search for other works by this author on: Oxford Academic PubMed Google Scholar Steinke Gisela, Steinke Gisela Search for other works by this author on: Oxford Academic PubMed Google Scholar Dieter Petzold Dieter Petzold 4Hygiene-Institut der Universitat, D-34 Gottingen, West Germany. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 53, Issue 1, July 1974, Pages 195–199, https://doi.org/10.1093/jnci/53.1.195 Published: 01 July 1974 Article history Received: 03 January 1974 Accepted: 25 March 1974 Published: 01 July 1974
Incidence and Secular Trend of Multiple Myeloma in Olmsted County, Minnesota: 1965-77&lt;xref ref-type="fn" rid="fn2"&gt;2&lt;/xref&gt;
Authors: A Linos, R A Kyle, W M O'Fallon, L T Kurland
Journal: JNCI Journal of the National Cancer Institute (1981)

The average annual age-adjusted incidence rate of multiple myeloma for Olmsted County, Minnesota, for 1965-77 was 2.7/10(5) person-years. The sex-specific rates for males and females were 3.5 and 2.2/10(5) person-years, respectively; the male-to-female incidence ratio was 1.6:1.0. These rates were similar to rates reported for white people from the Third National Cancer Survey and the New York and Connecticut tumor registries. This average incidence rate did not appear different from the rate for the 20-year period 1945-64 in Olmsted County. The incidence of multiple myeloma was not shown to have increased in the past 33 years, and the observed increase in mortality from this disease reported in other parts of the country indicated improved case ascertainment during recent years, a factor not likely to be important in Olmsted County.
Optimal combined modality treatment improves outcome of locally advanced bladder cancer: Analysis of SWOG 8710
Authors: Z. A. Dotan, D. F. Bajorin, B. H. Grossman, H. W. Herr
Journal: Journal of Clinical Oncology (2005)

4531 Background: Radical cystectomy [RC] is the standard treatment for muscle-invasive bladder cancer but cures only 50% of patients (pts). Recently, a randomized, cooperative group trial reported that neoadjuvant chemotherapy [NCT] improves postcystectomy survival (PCS) (NEJM 349:859) and surgical factors favorably impacted the freedom from local recurrence (LR) and PCS (JCO 22:2781). We evaluated the impact of both treatments on LR and PCS among patients with locally advanced bladder cancer. Methods: SWOG 8710 enrolled 317 patients (pts) with clinical stage T2-T4a, N0, M0 of which 307 (97%) had complete records available for review. Median follow-up was of 8.4 years. 154 pts (50%) were randomized to receive 3 cycles of MVAC prior to cystectomy. RC was performed in 268 (87%) pts. Reasons for not performing RC (N= 39) were: aborting the surgery at time of exploration in 22 pts (56%); patient refusal in 16 (41%); and, progression of bladder tumor in 1 pt (3%). In pts for which the procedure was aborted at time of exploration, 17 (81%) had positive nodes and 5 (19%) were classified as non-resectable. LR was detected in 75/307 (24%) pts and 136/307 (44%) died. Clinical variables including NCT (yes vs no), number of pelvic lymph nodes (PLN > 10 vs ≤10), surgical margin (SM + vs -) and completion of RC (yes vs no) were tested in univariate and multivariate analysis for associations with PCS and LR. Results: PCS was associated on multivariate analysis with NCT (HR 1.39; 95% CI 1–1.98; P=0.06), RC (HR 2.88; 95% CI 1.92–4.33; P<0.001) and PLN >10 (HR 2.38; 95% CI 1.58–3.59; P<0.001). 5 year PCS and 5 year freedom from LR were 81% and 91% in pts who had NCT/RC/PLN ≥10 (n=66), 66% and 90%, in pts with RC/PLN≥10 (n=60), 55% and 73% in RC/MVAC/PLN<10 (N=49) and 39% and 66% in RC/PLN <10 (n=44). 5 years survival of pts with (+) surgical margin (N=25) and those who had no cystectomy (N=39) was 0% and 11% with a median survival of 1.2 and 1.1 years, respectively. Conclusions: Patients with locally advanced bladder cancer have significantly improved freedom from local recurrence and survival when therapy is optimized, ie neoadjuvant chemotherapy, cystectomy and adequate lymphadenectomy. Patients who failed to undergo radical cystectomy had a dismal prognosis No significant financial relationships to disclose.
Somatic BRCA status in ovarian tumors
Authors: B. Hennessy, K. Timms, M. S. Carey, A. Gutin, R. Broaddus, A. Gonzalez-Angulo, J. Lanchbury, K. Lu, G. B. Mills
Journal: Journal of Clinical Oncology (2009)

5528 Background: The combined prevalence of BRCA1/2 mutations in germline DNA derived from a population of invasive ovarian cancer patients is up to 15.3%. PARP inhibitor trials are ongoing in patients who carry germline BRCA1/2 mutations. It is important to know whether somatic (non-germline) BRCA changes are present in ovarian tumors, given the predicted sensitivity of BRCA mutation-carrying tumors to PARP inhibitors and other DNA damaging agents. However, a large cohort of ovarian tumor tissues has not been studied to determine the frequency of BRCA deficiency due to additional somatic changes. Methods: BRCA1/2 exons/flanking regions were sequenced in 235 high-grade ovarian cancers and 38 ovarian cancer cell lines. In 112 tumors, we also performed gene expression analysis and copy number arrays with ultradense probe tiling throughout both BRCA genes. Results: For BRCA1, 31 tumors (13.2%) harbored mutations: 23 known deleterious mutations, 1 suspected deleterious mutation, 3 novel indels, 1 novel mis-sense and 3 novel nonsense mutations. For BRCA2, 12/178 sequenced tumors (6.7%) harbored mutations: 8 known deleterious mutations, 1 suspected deleterious mutation and 3 novel indels. Only 3 BRCA1 mutations were detected in 2 cell lines, two known deleterious and 1 a novel 29 base pair deletion. One cell line thus appears to have both a germline and a somatic mutation. BRCA mutation status was associated with a trend to improved progression-free survival (PFS) in univariate analysis (p = 0.17). However, BRCA deficiency (defined by BRCA1/2 gene expression loss (4 tumors) and homozygous deletion (1 tumor) in addition to mutations) was associated with improved PFS in univariate (p = 0.04) and multivariate (p = 0.03) analyses. Conclusions: The frequency of BRCA1/2 mutations in ovarian tumors detected by sequencing regardless of family history is ≈20%, higher than the expected prevalence of germline mutations. In both BRCA1/2 genes, almost 25% of mutations in tumor tissue were novel and not previously seen in germline DNA. We are now sequencing corresponding germline DNA to determine the exact number of these novel mutations that are somatic. Direct analysis of ovarian tumor tissue is likely to expand the number of women with BRCA-deficient tumors beyond that detectable by germline sequencing. [Table: see text]
Effect of metronomic use of zoledronic acid (ZOL) on antitumor and antiosteoclastic effects in breast cancer patients with bone metastasis
Authors: H. Xi-Chun, X. Zhao, X. Xu, H. Guo, Z. Wang, X. Guo, J. Chen, J. Wu, Z. Shao, J. Li, B. Zhu
Journal: Journal of Clinical Oncology (2009)

e14603 Background: Zoledronic acid (ZOL) can reduce the risk of skeletal-related events (SREs) and may have direct and indirect antitumor effects, which have been shown in animal models, pilot clinical studies as well as in recent phase III randomized trials. However, the pharmacokinetics of the drug in breast cancer patients remains to be elucidated and optimized. The purpose of this randomized study was to compare the effects of ZOL on osteoclasts and angiogenesis between a weekly low-dose versus a conventional dosage. Methods: Sixty breast cancer patients with bone metastases were recruited in this randomized phase II clinical study. The participants either received ZOL 1mg IV weekly for 4 doses or a single dose of ZOL 4mg IV. No other antitumor treatments were administered. During the first month after initial infusion of ZOL, serial blood samples were collected on day 1, 15 and 29 measuring markers for bone resorption (NTx), angiogenesis (VEGF), and tumor burden (CEA and CA15–3). Results: Compared to a single-dose administration, weekly low dose of ZOL resulted in a greater reduction in serum levels of VEGF and NTx, with a significant trend over time during one month observation. There were no statistically significant differences in circulating levels of CEA and CA15–3 between the two dosing regimens. Patients who received metronomic ZOL had a longer median time to disease progression (TTP) (7.0 months, 95%CI, 6.1–7.9 months) than those who had a single dose of ZOL (2.8 months, 95%CI, 0–5.7 months; p=0.076). Conclusions: The metronomic use of low-dose ZOL 1 mg appeared to be more effective than the conventional regimen in the long-lasting reduction of VEGF and NTx, and in prolonging TTP. This dosing schedule should be further assessed in phase III trials as we demonstrated that ZOL 1mg has greater antitumor properties in our study. No significant financial relationships to disclose.
Chemotherapy and hormonal therapy in combination.
Authors: V Hug, H Thames, J Clark
Journal: Journal of Clinical Oncology (1988)

The advantage of adding hormones to chemotherapy for the treatment of patients with breast carcinoma is uncertain, and benefits and disadvantages have been reported. An analysis of published randomized clinical trials reveals that the growth function (differentiation-inducing function v mitogenic function) of the hormone used may determine the ultimate benefit of combined modality treatments.
IGF-1 Receptor Differentially Regulates Spontaneous and Evoked Transmission via Mitochondria at Hippocampal Synapses
Authors: Neta Gazit, Irena Vertkin, Ilana Shapira, Martin Helm, Edden Slomowitz, Maayan Sheiba, Yael Mor, Silvio Rizzoli, Inna Slutsky
Journal: Neuron (2016)

The insulin-like growth factor-1 receptor (IGF-1R) signaling is a key regulator of lifespan, growth, and development. While reduced IGF-1R signaling delays aging and Alzheimer's disease progression, whether and how it regulates information processing at central synapses remains elusive. Here, we show that presynaptic IGF-1Rs are basally active, regulating synaptic vesicle release and short-term plasticity in excitatory hippocampal neurons. Acute IGF-1R blockade or transient knockdown suppresses spike-evoked synaptic transmission and presynaptic cytosolic Ca2+ transients, while promoting spontaneous transmission and resting Ca2+ level. This dual effect on transmitter release is mediated by mitochondria that attenuate Ca2+ buffering in the absence of spikes and decrease ATP production during spiking activity. We conclude that the mitochondria, activated by IGF-1R signaling, constitute a critical regulator of information processing in hippocampal neurons by maintaining evoked-to-spontaneous transmission ratio, while constraining synaptic facilitation at high frequencies. Excessive IGF-1R tone may contribute to hippocampal hyperactivity associated with Alzheimer's disease.Video Abstracthttps://www.cell.com/cms/asset/26b1210f-96ee-4d0c-8706-e8357714f59e/mmc3.mp4Loading ...(mp4, 44.6 MB) Download video
Impaired Awareness of Hypoglycemia in Adults With Type 1 Diabetes Is Not Associated With Autonomic Dysfunction or Peripheral Neuropathy
Authors: Sandra E. Olsen, Marit R. Bjørgaas, Bjørn O. Åsvold, Trond Sand, Marit Stjern, Brian M. Frier, Kristian B. Nilsen
Journal: Diabetes Care (2015)

OBJECTIVE Impaired awareness of hypoglycemia (IAH) is a risk factor for severe hypoglycemia in people with insulin-treated diabetes; autonomic neuropathy has been suggested to underlie its development. The aim was to evaluate a putative association between IAH and autonomic dysfunction using novel and sensitive measures of autonomic neural function. RESEARCH DESIGN AND METHODS Sixty-six adults with type 1 diabetes were studied, 33 with IAH and 33 with normal awareness of hypoglycemia (NAH), confirmed by formal testing. Participants were matched for age, sex, and diabetes duration. Clinical and laboratory evaluations included extensive autonomic function testing, peripheral nerve conduction studies, and quantitative sensory testing. Composite abnormality Z scores were used for group comparisons. RESULTS The IAH and NAH group had similar median (interquartile range) age of 48 (14.5) vs. 47 (14.5) years, diabetes duration of 30 (13.5) vs. 31 (13.5) years, and mean ± SD HbA1c 7.8 ± 2.2% vs. 8.1 ± 1.9%, respectively. The autonomic composite Z score did not differ between the two groups (mean difference −0.15, 95% CI −0.46, 0.16; P = 0.33), nor did the thermal detection (mean difference 0.15, 95% CI −0.31, 0.61; P = 0.51) or nerve conduction scores (mean difference 0.03, 95% CI −0.43, 0.49; P = 0.89). CONCLUSIONS In adults with type 1 diabetes, IAH was not associated with autonomic dysfunction or peripheral neuropathy.
Incidence and severity of oral mucositis induced by conventional chemotherapy: A comprehensive prospective analysis of 227 cancer patients.
Authors: N. Nishimura, M. Nishimura, S. Yamada, K. Ueda, Y. Mishima, M. Yokoyama, T. Saotome, Y. Terui, S. Takahashi, K. Hatake
Journal: Journal of Clinical Oncology (2010)

e19634 Background: Oral mucositis (OM), which may decrease treatment effectiveness by dose reduction and impair the patient's quality of life, is thought to be a frequent complication associated with cancer chemotherapy. However, the incidence and severity of OM induced by chemotherapy in patient with various solid tumor and hematological malignancies is unclear. The purpose of this study is to determine the incidence and severity of OM and it's sequelae in patients receiving conventional chemotherapy for various malignancies and clarify the risk factors of OM. Methods: 227 patients (male 33%, female 66%) who received chemotherapy for head and neck cancer, esophageal cancer, colorectal cancer, breast cancer and hematological malignancies in our institute from January 2007 to December 2008 were examined by questionnaires about OM onset, OM severity by CTCAE and their associated outcomes of anorexia, diarrhea, dysphasia. Results: The incidence of OM was highest in patients with breast cancer (76.5%), then, head and neck cancer (67.7%), colorectal cancer (63%), esophageal cancer (57.8%), and malignant lymphoma (42.9%). Patients who had breast cancer and head and neck cancer experienced severe mucositis (≧ Grade 2) with 26% and 23% respectively. The high risk regimens for mucositis were DCF (85.7%), FOLFILI (80%), CAF (78.8%), AC (70.6%) and FOLFOX (60%) in order. OM was associated with gastrointestinal adverse events, anorexia, diarrhea and dysphasia which worsened quality of life. There was no correlation between incidence of OM and prior therapy, PS, oral care or laboratory data but lower CRP. There was no statistically significant positive correlation between OM and overall survival after chemotherapy in patients with cancer. Conclusions: The OM frequently occurs in patients with various solid tumors receiving conventional chemotherapy; however, the incidence and severity differ with the regimen respectively. Adequate preventive treatment for OM depends on the chemotherapy regimen. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Chugai Pharma, Janssen Pharmaceutical K.K. Bayer, Bristol-Myers Squibb, Chugai Pharma, Janssen Pharmaceutical K.K., Kyowa Hakko Kirin, Taiho Pharmaceutical, Yakult Honsha
Routine positron emission tomography (PET) and selective mediastinoscopy is as good as routine mediastinoscopy to rule out N2 disease in non-small cell lung cancer (NSCLC)
Authors: M. Serra, L. Cirera, R. Rami-Porta, R. Bastus, S. Gonzalez, M. Simó, M. Domenech, E. Barbeta, J. M. Soler, J. Belda
Journal: Journal of Clinical Oncology (2006)

7031 Background: To evaluate the presence of mediastinal lymph node spread of NSCLC after changing the clinical staging protocol from routine to selective surgical mediastinal exploration (SME) based on PET. Methods: From 1994 to 2003, routine SME (mediastinoscopy, parasternal mediastinotomy or extended cervical mediastinoscopy) was performed to 655 patients (pts) with NSCLC as the last clinical staging procedure prior to thoracotomy. Those with no mediastinal involvement underwent thoracotomy with lung resection (T) and systematic nodal dissection (SND). From 2004, PET was routinely done in 90 pts and SME was reserved for those with positive mediastinal or hiliar uptake on PET, mediastinal lymph node diameter greater than 1cm in shorter axis on computerized tomography, and in tumors contacting with the mediastinum. All other pts and those with negative SME underwent T and SND. Results: Among 655 pts studied between 1994 and 2003, 236 (36%) had positive SME; 419 underwent T and SND and 40 (6.1%) were classsified as pN2. Of the 90 evaluable pts with PET, 27 had increased uptake in the mediastinum an 17 had positive SME; the remaining 10 ptes with negative SME underwent T and SND and 7 of them were found to have no nodal disease (false positive PET), but three of them were found to have nodal disease. Of the 63 pts with no uptake in the mediastinum, 29 underwent SME for reasons stated above: 5 SME was positive; in 24 SME was negative and the patients underwent T and SND: 21 were pN0 and 3 were pN2. Only 1 tumor of the remaining 34 pts with negative PET who underwent T and SND without SME was classified pN2. Additionally, in 1 pt PET detected N2 disease but not N3. 4 (4.5%) pts with pN2 disease were clinically understaged (negative PET and negative SME) and underwent thoracotomy. 3 pts with positive PET who underwent SME were classified pN0, but they were pN2 (false negative SME). In total, 7 (7.8%) pts with pN2 disease were clinically understaged and underwent T. This rate is not statisticallly different from the 6.1% pN2 tumor found after routine SME. Conclusions: In this preliminary study, this new clinical staging protocol with routine PET and selective SME saves up to 35% of SME and yields a similar rate of pN2 disease compared to routine SME. No significant financial relationships to disclose.
Different Risks of Thrombosis in Four Coagulation Defects Associated With Inherited Thrombophilia: A Study of 150 Families
Authors: Ida Martinelli, Pier Mannuccio Mannucci, Valerio De Stefano, Emanuela Taioli, Valentina Rossi, Francesca Crosti, Katia Paciaroni, Giuseppe Leone, Elena M. Faioni
Journal: Blood (1998)